Condition: Psoriatic Arthritis · Axial Spondyloarthritis · Sponsor: UCB Biopharma SRL
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.
This description comes directly from the study's public registry record.
UCB Cares · +18445992273 · ucbcares@ucb.com
UCB Cares · +18445992273
Always discuss trial participation with your own doctor first.
| Pa0019 114 | Peoria, Arizona, United States | Recruiting |
| Pa0019 127 | Apple Valley, California, United States | Recruiting |
| Pa0019 111 | Covina, California, United States | Recruiting |
| Pa0019 119 | Fullerton, California, United States | Recruiting |
| Pa0019 117 | Riverside, California, United States | Recruiting |
| Pa0019 125 | San Leandro, California, United States | Recruiting |
| Pa0019 126 | Temecula, California, United States | Recruiting |
| Pa0019 141 | Upland, California, United States | Recruiting |
| Pa0019 120 | Whittier, California, United States | Recruiting |
| Pa0019 128 | Whittier, California, United States | Recruiting |
| Pa0019 123 | Fort Collins, Colorado, United States | Recruiting |
| Pa0019 143 | Ormond Beach, Florida, United States | Recruiting |
+ 51 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07290036